Interim Analysis of the Phase III CLL10 Trial: FCR versus Bendamustine/Rituximab for Fit Patients with Previously Untreated CLL


Interim Analysis of the Phase III CLL10 Trial: FCR versus Bendamustine/Rituximab for Fit Patients with Previously Untreated CLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Eichhorst B et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Proc ASH 2013;Abstract 526.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.